Patent details

EP3018204 Title: A NOVEL CLASS OF THERAPEUTIC PROTEIN BASED MOLECULES

Basic Information

Publication number:
EP3018204
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP151803715
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
A NOVEL CLASS OF THERAPEUTIC PROTEIN BASED MOLECULES
French Title of Invention:
NOUVELLE CLASSE DE MOLÉCULES À BASE DE PROTÉINES THÉRAPEUTIQUES
German Title of Invention:
NEUARTIGE KLASSE THERAPEUTISCHER PROTEINBASIERTER MOLEKÜLE
SPC Number:

Dates

Filing date:
21/07/2005
Grant date:
12/04/2017
EP Publication Date:
11/05/2016
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
12/04/2017
EP B1 Publication Date:
12/04/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
21/07/2017
Expiration date:
21/07/2025
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
12/04/2017
 
 

Name:
Ansun Biopharma, Inc.
Address:
3030 Callan Road, San Diego CA 92121, United States (US)

Inventor

1

Name:
FANG, Fang
Address:
United States (US)

2

Name:
MALAKHOV, Michael
Address:
United States (US)

Priority

Priority Number:
939262
Priority Date:
10/09/2004
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/00; A61K 38/47; A61K 39/00; C07H 21/04; C12N 1/20; C12N 9/24; C12N 15/00;

Publication

European Patent Bulletin

1

Issue number:
201715
Publication date:
12/04/2017
Description:
Grant (B1)

2

Issue number:
201719
Publication date:
10/05/2017
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/11/2017 Outgoing Correspondence 1